EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Understanding the prevalence, antimicrobial resistance, and public health challenges of Acinetobacter baumannii in India and China

Naji Naseef Pathoor, Pitchaipillai Sankar Ganesh, Rajesh Kanna Gopal

Journal of Applied Microbiology · 02.05.2025 · 136 (5)

DOI: 10.1093/jambio/lxaf102 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Applied Microbiology, online erschienen am 30.04.2025. Verfasst von Naji Naseef Pathoor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Centre for infectious Diseases, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Scienc…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 103 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Acinetobacter baumannii (A. baumannii) is a globally recognized notorious pathogen for its high levels of antibiotic resistance, posing severe challenges in healthcare settings, particularly in the most populated countries, India and China. This review compares its epidemiology, resistance patterns, and management strategies in both countries, highlighting its role in healthcare-associated infections and the ongoing challenges in controlling its spread. Methods and results A comprehensive review of recent literature was conducted, analyzing studies from both countries to assess the prevalence, resistance trends, and risk factors associated with A. baumannii infections. In India, A. baumannii was found to be responsible for 22.3% of hospital-acquired pneumonia cases, with carbapenem resistance rates exceeding 70%. The emergence of New Delhi Metallo-β-lactamase (NDM)-producing strains has intensified the challenge. Meanwhile, the prevalence of multidrug-resistant (MDR) strains has risen to 74.7%. In China, A. baumannii accounts for 35.7%–52.7% of hospital-acquired pneumonia cases, with carbapenem resistance rates exceeding 70% and MDR strains reaching up to 63.8%. Both China and other countries have witnessed a rise in extensively drug-resistant (XDR) strains, further complicating treatment options and contributing to increased morbidity and mortality rates.

Conclusions

The review emphasizes how important it is to implement focused treatments, antimicrobial stewardship initiatives, and international cooperation in order to fight A. baumannii.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acinetobacter baumanniiAcinetobacter InfectionsAnti-Bacterial AgentsHumansChinaIndiaPrevalenceDrug Resistance, Multiple, BacterialCross InfectionPublic HealthCarbapenemsRisk Factors

Stichwörter der Autor:innen

A. baumanniiChinaIndiaepidemiologyhospital settingsmultidrug resistance

Substanzen

Anti-Bacterial AgentsCarbapenems

Autor:innen und Institutionen

  • Department of Microbiology, Centre for infectious Diseases, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences (SIMATS), Saveetha University (Deemed to be University), Chennai, 6…

Zitieren

APA

Pathoor, N. N., Ganesh, P. S., & Gopal, R. K. (2025). Understanding the prevalence, antimicrobial resistance, and public health challenges of Acinetobacter baumannii in India and China. Journal of Applied Microbiology, 136(5). https://doi.org/10.1093/jambio/lxaf102

Vancouver

Pathoor NN, Ganesh PS, Gopal RK. Understanding the prevalence, antimicrobial resistance, and public health challenges of Acinetobacter baumannii in India and China. Journal of Applied Microbiology. 2025;136(5). doi:10.1093/jambio/lxaf102

BibTeX
@article{Pathoor2025,
  author = {Pathoor, Naji Naseef and Ganesh, Pitchaipillai Sankar and Gopal, Rajesh Kanna},
  title = {Understanding the prevalence, antimicrobial resistance, and public health challenges of Acinetobacter baumannii in India and China},
  journal = {Journal of Applied Microbiology},
  year = {2025},
  volume = {136},
  number = {5},
  doi = {10.1093/jambio/lxaf102}
}
Kostenlos starten →